Alexandria Co. For Pharmaceuticals & Chemical Industries manufactures and trades in pharmaceutical products for human and veterinary use.
Price History & Performance
|Historical stock prices|
|Current Share Price||ج.م137.14|
|52 Week High||ج.م130.60|
|52 Week Low||ج.م159.90|
|1 Month Change||1.54%|
|3 Month Change||1.59%|
|1 Year Change||-8.53%|
|3 Year Change||4.94%|
|5 Year Change||180.28%|
|Change since IPO||320.68%|
Recent News & Updates
|AXPH||EG Pharmaceuticals||EG Market|
Return vs Industry: AXPH underperformed the EG Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: AXPH underperformed the EG Market which returned 8.2% over the past year.
Stable Share Price: AXPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: AXPH's weekly volatility (4%) has been stable over the past year.
About the Company
Alexandria Co. For Pharmaceuticals & Chemical Industries manufactures and trades in pharmaceutical products for human and veterinary use. The company offers products in various pharmaceutical areas, such as analgesics, antipyretics, anti-inflammatory, cardiovascular, loop diuretic, hypotensive, haemostatic, antibiotics, antibacterial, anthelmintic, antimalarial, antiprotozoal, antifungals, antitussive, local anaesthetics, gastrointestinal, antihistamine, antispasmodics, bronchodilator and anti-asthma, anti-gout, mydriatics, miotics, decongestants, antiepileptic, and antidiabetic. It also provides various products, including H2 receptor antagonists, opioid analgesics, antineoplastic and immunosuppressant, anti-depressent, anticoagulants, local anaesthetic dental injections, vitamins, local decongestant antihistamines, other analgesics, skeletal muscle relaxants, and other products, as well as drugs for hepatic disorders, minor skin disorders, and myasthenia gravis.
Alexandria For Pharmaceuticals & Chemical Industries Fundamentals Summary
|AXPH fundamental statistics|
Is AXPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AXPH income statement (TTM)|
|Cost of Revenue||ج.م841.45m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||23.40|
|Net Profit Margin||10.54%|
How did AXPH perform over the long term?See historical performance and comparison
11.3%Current Dividend Yield
Is Alexandria For Pharmaceuticals & Chemical Industries undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AXPH (EGP137.14) is trading below our estimate of fair value (EGP556.7)
Significantly Below Fair Value: AXPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AXPH is poor value based on its PE Ratio (5.9x) compared to the EG Pharmaceuticals industry average (5.5x).
PE vs Market: AXPH is good value based on its PE Ratio (5.9x) compared to the EG market (12.3x).
Price to Earnings Growth Ratio
PEG Ratio: AXPH is good value based on its PEG Ratio (0.2x)
Price to Book Ratio
PB vs Industry: AXPH is good value based on its PB Ratio (1.2x) compared to the EG Pharmaceuticals industry average (1.3x).
How is Alexandria For Pharmaceuticals & Chemical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AXPH's forecast earnings growth (28.5% per year) is above the savings rate (9.1%).
Earnings vs Market: AXPH's earnings (28.5% per year) are forecast to grow faster than the EG market (14.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AXPH's revenue (15.5% per year) is forecast to grow faster than the EG market (9.9% per year).
High Growth Revenue: AXPH's revenue (15.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AXPH's Return on Equity is forecast to be high in 3 years time (20.9%)
How has Alexandria For Pharmaceuticals & Chemical Industries performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AXPH has a high level of non-cash earnings.
Growing Profit Margin: AXPH's current net profit margins (10.5%) are lower than last year (16.6%).
Past Earnings Growth Analysis
Earnings Trend: AXPH's earnings have grown by 12.9% per year over the past 5 years.
Accelerating Growth: AXPH's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: AXPH had negative earnings growth (-31.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (10%).
Return on Equity
High ROE: AXPH's Return on Equity (20%) is considered low.
How is Alexandria For Pharmaceuticals & Chemical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: AXPH's short term assets (EGP526.8M) exceed its short term liabilities (EGP199.8M).
Long Term Liabilities: AXPH's short term assets (EGP526.8M) exceed its long term liabilities (EGP7.5M).
Debt to Equity History and Analysis
Debt Level: AXPH's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: AXPH's debt to equity ratio has reduced from 3% to 0.3% over the past 5 years.
Debt Coverage: AXPH's debt is well covered by operating cash flow (5605.5%).
Interest Coverage: AXPH earns more interest than it pays, so coverage of interest payments is not a concern.
What is Alexandria For Pharmaceuticals & Chemical Industries's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AXPH's dividend (11.3%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).
High Dividend: AXPH's dividend (11.3%) is in the top 25% of dividend payers in the EG market (7.43%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, AXPH has been paying a dividend for less than 10 years.
Growing Dividend: AXPH's dividend payments have increased, but the company has only paid a dividend for 8 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (66.2%), AXPH's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Afaf El Motaz BillahMubarak serves as Chairman and Managing Director of Alexandria Company For Pharmaceuticals & Chemical Industries. Dr. Mubarak served as a Non-Executive Director of The Arab Drug Com...
Experienced Management: AXPH's management team is considered experienced (4 years average tenure).
Experienced Board: AXPH's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alexandria Co. For Pharmaceuticals & Chemical Industries's employee growth, exchange listings and data sources
- Name: Alexandria Co. For Pharmaceuticals & Chemical Industries
- Ticker: AXPH
- Exchange: CASE
- Founded: 1962
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م685.700m
- Shares outstanding: 5.00m
- Website: https://www.alexcopharma.net
- Alexandria Co. For Pharmaceuticals & Chemical Industries
- End of Gamila Bohreid Road
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 14:30|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.